Filing Details
- Accession Number:
- 0001209191-22-038713
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-06-22 17:09:25
- Reporting Period:
- 2022-06-17
- Accepted Time:
- 2022-06-22 17:09:25
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1845337 | Day One Biopharmaceuticals Inc. | DAWN | () | DE |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1708269 | Atlas Venture Fund Xi, L.p. | 300 Technology Square, 8Th Floor Cambridge MA 02139 | No | No | Yes | No | |
1759241 | Atlas Venture Opportunity Fund I, L.p. | 300 Technology Square, 8Th Floor Cambridge MA 02139 | No | No | Yes | No | |
1780065 | Atlas Venture Associates Opportunity I, L.p. | 300 Technology Square, 8Th Floor Cambridge MA 02139 | No | No | Yes | No | |
1780066 | Atlas Venture Associates Opportunity I, Llc | 300 Technology Square, 8Th Floor Cambridge MA 02139 | No | No | Yes | No | |
1780067 | Atlas Venture Associates Xi, Llc | 300 Technology Square, 8Th Floor Cambridge MA 02139 | No | No | Yes | No | |
1780068 | Atlas Venture Associates Xi, L.p. | 300 Technology Square, 8Th Floor Cambridge MA 02139 | No | No | Yes | No | |
1885327 | Atlas Venture Opportunity Fund Ii, L.p. | 300 Technology Square, 8Th Floor Cambridge MA 02139 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-06-17 | 766,667 | $15.00 | 766,667 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 7,210,242 | Indirect | See footnote |
Common Stock | 15,714 | Indirect | See footnote |
Common Stock | 991,396 | Indirect | See footnote |
Footnotes
- The shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.
- The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.
- The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of its pecuniary interest therein, if any.
- The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.